These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 15800902

  • 1. Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
    Xu GW, Mymryk JS, Cairncross JG.
    Int J Cancer; 2005 Aug 20; 116(2):187-92. PubMed ID: 15800902
    [Abstract] [Full Text] [Related]

  • 2. Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Xu GW, Nutt CL, Zlatescu MC, Keeney M, Chin-Yee I, Cairncross JG.
    Cancer Res; 2001 May 15; 61(10):4155-9. PubMed ID: 11358839
    [Abstract] [Full Text] [Related]

  • 3. Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
    Xu GW, Mymryk JS, Cairncross JG.
    J Neurooncol; 2005 Sep 15; 74(2):141-9. PubMed ID: 16193384
    [Abstract] [Full Text] [Related]

  • 4. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
    Hayashi T, Adachi K, Ohba S, Hirose Y.
    J Neurooncol; 2013 Nov 15; 115(2):169-78. PubMed ID: 23943501
    [Abstract] [Full Text] [Related]

  • 5. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
    Chen CC, Taniguchi T, D'Andrea A.
    J Mol Med (Berl); 2007 May 15; 85(5):497-509. PubMed ID: 17221219
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S, Hirose Y, Kawase T, Sano H.
    J Neurooncol; 2009 Dec 15; 95(3):307-316. PubMed ID: 19517066
    [Abstract] [Full Text] [Related]

  • 7. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B.
    Oncogene; 2007 Jan 11; 26(2):186-97. PubMed ID: 16819506
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
    Papait R, Magrassi L, Rigamonti D, Cattaneo E.
    Biochem Biophys Res Commun; 2009 Feb 06; 379(2):434-9. PubMed ID: 19116135
    [Abstract] [Full Text] [Related]

  • 9. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
    Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD.
    Int J Oncol; 2001 Aug 06; 19(2):359-65. PubMed ID: 11445852
    [Abstract] [Full Text] [Related]

  • 10. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
    Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M.
    J Neurochem; 2006 Feb 06; 96(3):766-76. PubMed ID: 16405512
    [Abstract] [Full Text] [Related]

  • 11. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM, Ahmed MM, Chendil D, Moschel RC, Pegg AE.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [Abstract] [Full Text] [Related]

  • 12. Temozolomide induces senescence but not apoptosis in human melanoma cells.
    Mhaidat NM, Zhang XD, Allen J, Avery-Kiejda KA, Scott RJ, Hersey P.
    Br J Cancer; 2007 Nov 05; 97(9):1225-33. PubMed ID: 17968428
    [Abstract] [Full Text] [Related]

  • 13. Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
    Yamauchi T, Ogawa M, Ueda T.
    Mol Pharmacol; 2008 Jul 05; 74(1):82-91. PubMed ID: 18430789
    [Abstract] [Full Text] [Related]

  • 14. Pifithrin-alpha promotes p53-mediated apoptosis in JB6 cells.
    Kaji A, Zhang Y, Nomura M, Bode AM, Ma WY, She QB, Dong Z.
    Mol Carcinog; 2003 Jul 05; 37(3):138-48. PubMed ID: 12884365
    [Abstract] [Full Text] [Related]

  • 15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.
    Health Technol Assess; 2007 Nov 05; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [Abstract] [Full Text] [Related]

  • 16. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM.
    Clin Cancer Res; 2002 Aug 05; 8(8):2725-34. PubMed ID: 12171906
    [Abstract] [Full Text] [Related]

  • 17. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.
    Hirose Y, Berger MS, Pieper RO.
    Cancer Res; 2001 Aug 01; 61(15):5843-9. PubMed ID: 11479224
    [Abstract] [Full Text] [Related]

  • 18. Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
    Kang KB, Zhu C, Yong SK, Gao Q, Wong MC.
    Mol Cancer; 2009 Aug 25; 8():66. PubMed ID: 19706164
    [Abstract] [Full Text] [Related]

  • 19. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
    Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G.
    Glia; 2002 Oct 25; 40(1):44-54. PubMed ID: 12237842
    [Abstract] [Full Text] [Related]

  • 20. Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation.
    Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M, Pratt WB.
    J Biol Chem; 2004 Jul 16; 279(29):30195-201. PubMed ID: 15145929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.